Insider Purchases: Inside the Buy
Tag: CEO Buys
CarMax (KMX): Where Insiders Keep Buying — And Cars Keep Driving Off (Mostly the Lot)
Insiders and institutions are revving up for CarMax’s comeback — even as used car sales slow and margins tighten. With shares 70% below their peak and a major digital overhaul underway, this could be the turnaround ride of the year. 🚘📉 Or just another trip to the mechanic.
W&T Offshore (WTI): CEO Buys Shares, But the Tide May Still Be Out
W&T Offshore (WTI): Deep Value or Deep Trouble?
Houston’s oil-and-gas veteran has been drilling for 40 years — and shareholders are still waiting to strike gold. With the CEO buying more shares while shorts circle overhead, the battle for the Gulf of America’s future is heating up. Production’s up, cash flow’s steady, and the dividend still drips — but with a stock 97% below its all-time high, is this a comeback story or a cautionary tale?
CEO Bought Shares Higher A Year Ago. Will RH Restore Investor Confidence?
RH stock has crashed, but its CEO is still buying, funds are backing, and Paris is shining. With shorts circling and debt looming, is RH a comeback story—or just a fancy couch with shaky legs?
Insiders Think Marvell Is a Wonder at Current Price; Should You Emulate the CEO, CFO, and Presidents and Buy MRVL?
Insiders, buybacks, and AI growth — oh my! Marvell Technology’s execs just bought millions in stock. With a $5B buyback, should you marvel too?
CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?
Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?
CEO and Michael Burry of Scion Asset Management Have Bought Shares of Bruker Corporation (BRKR). Should You Too, Or Is It a Value Trap?
CEO insider buys + Michael Burry’s 15% portfolio bet make Bruker (BRKR) hard to ignore. But is it a hidden gem in science… or a costly lab experiment?
Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?
Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈
Revisiting Why MSCI’s CEO Bought Shares Multiple Times Over the Past Year
MSCI’s CEO has spent over $11M buying shares in the past year. With institutions holding nearly 95% and margins above 60%, is MSCI worth the premium?
Lyft’s CEO Keeps Buying Shares. Are They About to Lift Off?
Lyft’s CEO keeps buying stock while hedge funds pile in. With profits, free cash flow, and share buybacks, could LYFT finally lift off—or hit roadblocks? 🚗📈
CEO, CFO, COO, and President, CooperVision, Are All Buying Shares of The Cooper Companies. Should You?
The CEO, CFO, COO, and President of CooperCompanies all just bought shares. Insiders, institutions, and even the company itself are betting on the stock. Value play or just another lens cleaner? 👓💸